It might be easy to dismiss non-life-threatening diseases of the skin or nail as trivial, but their impact on physical and mental wellbeing can be significant. Such diseases are obvious targets for topical treatments, but the lack of effective formulations means patients are often faced with the prospect of oral…
List view / Grid view
The regulatory body said that due to uncertainties surrounding the long-term effectiveness of nivolumab (Opdivo), its cost-effectiveness estimates are too high.
The EMA's human medicines committee has adopted a positive opinion for eight medicines, recommending their marketing authorisation.
Novel particles could be incorporated into topical creams to treat dermatological conditions without systemic exposure to drugs.
The marketing license for ingenol mebutate gel (Picato) has been suspended by the MHRA due to studies showing an increased risk of skin malignancies from the drug.
The EMA will assess the marketing authorisation for the medication to see whether it is a cause of skin cancer in patients.
Evidence suggests the human papillomavirus plays a role in the development of some types of this skin cancer...